SCHEMBL7544095

SCHEMBL7544095

c1ccc(Nc2cc(-c3cccs3)[nH]n2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 5/20 0.64
KMT2A Q03164 5/20 0.53
MEN1 O00255 4/20 0.53
MAPT P10636 4/20 0.53
ALDH1A1 P00352 2/20 0.53
GAA P10253 2/20 0.53
TP53 P04637 1/20 0.53
TSHR P16473 1/20 0.53
HSD17B10 Q99714 1/20 0.53
APP P05067 1/20 0.52
ADORA3 P0DMS8 1/20 0.49
CHEK1 O14757 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
TNIK Q9UKE5 1/20 0.44
NFKB1 P19838 1/20 0.43
AHR P35869 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
PDE5A O76074 1/20 0.43
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21262401 0.87 FLT3 (0.63) FLT3KMT2AMEN1MAPTALDH1A1
SCHEMBL12038433 0.80 APP (0.59) FLT3KMT2AMEN1MAPTALDH1A1
SCHEMBL13312221 0.78 APP (0.78) FLT3KMT2AMEN1MAPTALDH1A1
SCHEMBL11964164 0.78 FLT3 (0.67) FLT3KMT2AMEN1POLBLMNA
SCHEMBL18434151 0.77 CHEK1 (0.67) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL3603791 0.75 FLT3 (0.53) FLT3KMT2AMEN1APPL3MBTL1
SCHEMBL21262442 0.73 TNIK (0.68) KMT2AMEN1MAPTGAATNIK
SCHEMBL1665919 0.72 ADORA3 (0.62) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL3502079 0.71 APP (0.50) FLT3KMT2AMEN1MAPTALDH1A1
SCHEMBL3602280 0.71 MAPT (0.58) KMT2AMEN1MAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6462069-B2 KINASE INHIBITORS; ANTICANCER AGENTS AGOURON PHARMACEUTICALS, INC. 2002-10-08 US disclosed
US-20020006952-A1 Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases LIGHPOINTE COMMUNICATION, INC. 2002-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006952-A1 Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases CDK3, CCNK, CDK1 FLT3 677/4885KMT2A 3744/4885MEN1 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.